Drug intelligence / Profile preview

KP8041

Development stage: Preclinical
Lead developer: K Pharma
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Parenteral

Overview

KP8041 is an investigational cell therapy consisting of induced pluripotent stem cell (iPS)-derived neural progenitor cells (iPS-NPCs). Developed by K Pharma, Inc. in collaboration with Osaka Medical Center, the program is an expansion of the company's KP8031 asset (which targets spinal cord injury) into the indication of chronic cerebral hemorrhage. The therapy aims to promote functional recovery in the brain following a hemorrhagic stroke by transplanting neural progenitor cells that can differentiate into neurons and glial cells, potentially integrating into the host tissue or providing neurotrophic support to damaged areas. KP8041 is currently in the preclinical stage of development.

Other names: iPS-derived neural progenitor cells

Beyond the preview

Go deeper on KP8041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP8041.

Explore the full profile